SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug may stop aggressive lymphoma from returning after treatment
Disease control Recruiting nowThis study tests whether the drug acalabrutinib, taken as a maintenance therapy after cell therapy (stem cell transplant or CAR T-cells), can help prevent relapse in patients with very high-risk large B-cell lymphoma. The trial includes 24 adults aged 18-70 with aggressive forms …
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat brain cancer
Disease control Recruiting nowThis early-phase study tests an experimental cell therapy called MB-CART19.1 for people with central nervous system lymphoma (CNSL) that has returned or not responded to prior treatments. The therapy uses a patient's own immune cells, modified to target cancer, and is made on-sit…
Matched conditions: SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC